|Bid||3.30 x 0|
|Ask||3.40 x 0|
|Day's Range||3.2000 - 3.4300|
|52 Week Range||2.0400 - 6.3500|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
NEW YORK, Feb. 15, 2019 /CNW/ -- The demand for security in the cannabis sector has increased substantially as more businesses are becoming operational and as a result, companies involved in fields such as cultivation, retail, and distribution are seeking security services. Primarily, security service companies dabbling in the cannabis industry offer services such as armored transportation, surveillance, alarms, sensors, and on-site guards. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023.
OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.
OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.
As we see an increase in agricultural technology being used to increase the yield, and quality, of cannabis products, companies across the space will have greater access to inventory to distribute their products. Considering the fact that legal marijuana is becoming a reality in a large portion of the United States, Canada, and abroad, investors that have historically written off cannabis companies, are now flocking in droves with excitement. Nabis Holdings (INNPF) (NAB), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Green Growth Brands Inc (GGBXF), and The Supreme Cannabis Company (SPRWF) are four cannabis companies worth keeping on your radar on Thursday.
OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.
CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / Marijuana stocks have managed to become one of the hottest topics in the news over the course of the past few years. The fact of the matter is that previously conceived notions on cannabis are being replaced by favorable public opinions supporting all possible uses of marijuana, namely as a means of treatment for patients suffering from a myriad of ailments. Global Consortium Inc (GCGX), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Trulieve Cannabis Corp (OTC PINK: TCNNF), and OrganiGram Holdings Inc (OGRMF) are four pot stocks looking to remain on high this month.
OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.
OTCQX:EMHTF) today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019. The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.
OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.
Emerald Health Therapeutics, Inc. (EMH.V) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.
OTCQX:EMHTF) is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).
NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.
OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.
Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.
OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.
VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.
The cannabis bubble has just about burst, but it's never too late to put your money in low-risk stocks like Canadian National Railway (TSX:CNR)(NYSE:CNI)
OTCQX:EMHTF) is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...